Take Solutions shareholders have overwhelmingly approved the appointment of Sunil Patra as Managing Director, marking a key leadership transition for the technology services firm. The special resolution was passed via postal ballot with near-unanimous support from public non-institutional investors, who cast 34,355,939 votes in favour.

The voting process concluded on August 14, 2026, with results declared on August 17, 2026. M/s. Hemang Satra & Associates served as the independent scrutinizer for the process, which was conducted through remote e-voting facilitated by Central Depository Services Limited (CDSL).

Voting Breakdown

The resolution required a special majority under Section 110 of the Companies Act, 2013. Promoter and promoter group entities held no shares eligible for voting in this ballot, nor did they participate. Public institutional investors also did not cast votes.

The entire participation came from public non-institutional shareholders, representing a significant portion of the company's shareholding base.

Parmeshvar Namdev Dhangare, Chairman and Director of Take Solutions, countersigned the scrutinizer's report. The company noted that no promoter group members were interested in the agenda item related to Mr. Patra's appointment.

What the Numbers Show

The voting pattern reveals a distinct concentration of engagement among retail and non-institutional investors. With promoters and institutions abstaining or holding zero votes in this specific ballot category, the 99.98% approval rate is driven entirely by public non-institutional shareholders. This suggests that while the broader institutional block may not have been active in this specific remote e-voting cycle, the active retail base strongly endorses the new management structure. The negligible dissent of only 7,301 votes (0.02%) indicates minimal opposition to the board's proposal.

Take Limited delivered a consolidated net profit of ₹106.26 lakhs (₹1.06 crore) for the quarter ended June 30, 2026 (Q1FY27), marking a decisive return to profitability from a net loss of ₹91.00 lakhs in Q1FY26. The Chennai-based healthcare technology company reported consolidated revenue from operations of ₹3,037.33 lakhs (₹30.37 crore), expanding significantly from nil revenue in the corresponding period last year. This turnaround was primarily driven by operational scaling and a drastic reduction in finance costs, which fell 99.62% year-on-year to just ₹0.07 lakhs, reflecting a cleaner capital structure.

The Board of Directors approved the unaudited standalone and consolidated financial results on August 11, 2026, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by A. Raghavendra Rao & Associates, the statutory auditors, who issued a limited review report confirming that the financial statements present a true and fair view in accordance with Ind AS 34. The company, formerly known as Take Solutions Limited, has also announced a strategic entry into the longevity and biohacking sector, leveraging its clinical research expertise.

Financial Performance Highlights

Standalone performance mirrored the consolidated results, with revenue from operations rising to ₹1,196.90 lakhs from ₹0.65 lakhs in Q1FY26. Standalone net profit turned positive at ₹96.83 lakhs, compared to a loss of ₹216.45 lakhs previously. Total income for the consolidated entity reached ₹3,170.11 lakhs, supported by other income of ₹132.78 lakhs. Basic and diluted earnings per share (EPS) turned positive at ₹0.07 per share, up from negative ₹0.06 per share in Q1FY26.

Strategic Shift to Longevity Market

Management highlighted the stabilization of the operational framework as a key enabler for future growth. Parmeshvar Dhangare, Chairman & Director, stated that the clean balance sheet and near-zero finance costs position the company to execute its next growth phase. The firm is targeting the global longevity market, projected to grow from USD 27.61 billion in 2025 to USD 67.03 billion by 2035. In India, the preventive healthcare market reached USD 197 billion in 2025, with anti-aging supplements expected to expand at a 9.5% CAGR through 2033. The strategy involves integrating science-backed nutraceuticals with digital tools for metabolic health tracking.

What the Numbers Show

The most striking aspect of the Q1FY27 results is the complete reversal of the cost structure regarding debt servicing. Finance costs plummeted from ₹17.50 lakhs to ₹0.07 lakhs, indicating either debt repayment or refinancing at negligible rates. This reduction directly contributed to the bottom-line turnaround, as operating expenses remained relatively controlled. While revenue generation is new for this quarter (nil in Q1FY26), the ability to generate ₹106.26 lakhs in net profit on ₹3,037.33 lakhs of revenue suggests an initial gross margin advantage, though sustainability will depend on scaling this model without proportional increases in employee benefits or other expenses, which currently stand at ₹7.40 lakhs and ₹29.58 lakhs respectively.